TGF-β and TNF-α producing effects of losartan and amlodipine on human mononuclear cell culture
KUBRA KAYNAR,
SUKRU ULUSOY, ERCUMENT OVALI, BIRGUL VANIZOR,
TAMER DIKMEN, SEMIH GUL,
Corresponding Author
KUBRA KAYNAR
Department of Nephrology,
Dr Kubra Kaynar, Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Nefroloji Bilim Dalı, 61080 Trabzon, Turkey. Email: [email protected]Search for more papers by this authorBIRGUL VANIZOR
Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey
Search for more papers by this authorKUBRA KAYNAR,
SUKRU ULUSOY, ERCUMENT OVALI, BIRGUL VANIZOR,
TAMER DIKMEN, SEMIH GUL,
Corresponding Author
KUBRA KAYNAR
Department of Nephrology,
Dr Kubra Kaynar, Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Nefroloji Bilim Dalı, 61080 Trabzon, Turkey. Email: [email protected]Search for more papers by this authorBIRGUL VANIZOR
Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey
Search for more papers by this authorSUMMARY:
Aim: The modulation of cytokine release, which affects adhesion of leucocytes to endothelial cells, and proliferation of peripheral blood mononuclear cells with antihypertensive drugs was explored.
Method: In the present study, mononuclear cells were incubated with losartan and amlodipine at concentrations of 10−6, 10−5 and 10−4 mol/L for 6 h. Transforming growth factor (TGF)-β and tumour necrosis factor (TNF)-α levels were measured. Proliferation of mononuclear cells were assessed at the same concentrations of amlodipine and losartan with the methylthiazoletetrazolium (MTT) test.
Results: Amlodipine was found to induce TGF-β synthesis from mononuclear cells with increasing concentrations, while it was found to inhibit TNF-α secretion with increasing concentrations. In contrast, losartan was found to induce TGF-β and TNF-α secretion with increasing concentrations.
Conclusion: Anti-atherosclerotic effects of amlodipine and losartan might be through increased secretion of TGF-β from mononuclear cells. Different results at different concentrations might be due to the pharmocokinetic differences of these drugs.
REFERENCES
- 1 Von Baeyer H, Hopfenmuller W, Riedel E. Atherosclerosis: Current concepts of pathophysiology and pharmacological intervention based on trial outcomes. Clin. Nephrol. 2003; 60: 31–48.
- 2 Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995; 25: 155–61.
- 3 Simon BC, Noll B, Maisch B. Endothelial dysfunction: Assessment of current status and approaches to therapy. Herz 1999; 24: 62–71.
- 4 Smith JK, Dykes R, Douglas JE. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281: 1722–7.
- 5 Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988; 242: 97–9.
- 6 Mancini GB. Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT. Can. J. Cardiol. 2000; 16: 5–7.
- 7 Dahlöf B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003.
- 8 Wu XJ, Huang L, Song DL. Effects of endothelial cell growth states on the proliferation and migration of vascular smooth muscle cells in vitro. Sheng Li Wue Bao 2003; 55: 554–9.
- 9 Robertson AKL, Rudling M, Zhou X. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Ýnvest. 2003; 112: 1342–50.
- 10 Grainger DJ, Kemp PR, Liu AC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460–62.
- 11 Argmann CA, Van Den Diepstraten CH, Sawyez CG. Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 2011–18.
- 12 Byington RP, Miller ME, Herrington D et al. Rationale, design and baseline characteristics of the prospective randomized evaluation of the vascular effects of norvasc trial (PREVENT). Am. J. Cardiol. 1997; 80: 1087–90.
- 13 Pitt B, Byington RP, Furberg CD. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–10.
- 14 Harano Y, Kagayama A, Hirose J. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 1995; 44: 315–19.
- 15 Baba T, Neugebauer S. The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidemic drugs on insulin sensitivity. Drugs 1994; 47: 383–404.
- 16 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87–90.
- 17 Tristano A, Eugenia Chollet M, Wilson ML. Telomerase activity in peripheral blood leukocytes from patients with essential hypertension. Med. Clin. 2003; 120: 365–9.
- 18 Mohler ER, Sorensen LC, Ghali JK. Role of cytokines in the mechanism of action of amlodipine: The PRAISE heart failure trial. Prospective randomized amlodipine survival evaluation. J. Am. Coll. Cardiol. 1997; 30: 35–41.
- 19 Matsumori A, Ono K, Nishio R. Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine 2000; 12: 294–7.
- 20 Fukuzawa M, Satoh J, Ohta S et al. Modulation of tumor necrosis factor-α production with anti-hypertensive drugs. Immunopharmacology 2000; 48: 65–74.
- 21 Pirich C, Schmid P, Fitscha P. Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Press. 1994; 3: 75–80.
- 22 Chaudri G, Clark IA. Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of tumor necrosis factor. J. Immunol. 1989; 143: 1290–94.
- 23 Yu T, Morita I, Shimokado K. Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction. Hypertension 2003; 42: 329–34.
- 24 Kranzhofer R, Browatzki M, Schmidt J. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem. Biophys. Res. Commun. 1999; 257: 826–8.
- 25 Di Paolo SD, Schena A, Stallone G. Captopril enhances transforming growth factor (TGF)-β1 expression in peripheral blood mononuclear cells: A mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation 2002; 74: 1710–15.
- 26 Nataraj C, Oliverio MI, Mannon RB. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J. Clin. Invest. 1999; 104: 1693–701.
- 27 Klahr S, Morrissey J. Angiotensin II and gene expression in the kidney. Am. J. Kidney Dis. 1998; 31: 171–6.
- 28 Tashiro H, Shimokawa H, Yamamoto K. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron. Artery Dis. 1997; 8: 143–7.
- 29 Park S, Yang WS, Lee SK. TGF-β1 down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells. Nephrol. Dial. Transplant. 2000; 15: 596–604.
Citing Literature
